Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 2
2002 3
2004 1
2005 3
2006 1
2007 3
2008 5
2009 8
2010 5
2011 8
2012 7
2013 9
2014 11
2015 6
2016 11
2017 13
2018 7
2019 10
2020 11
2021 9
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31974130

117 results

Results by year

Filters applied: . Clear all
Page 1
Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.
Prosperini L, Mancinelli C, Haggiag S, Cordioli C, De Giglio L, De Rossi N, Galgani S, Rasia S, Ruggieri S, Tortorella C, Pozzilli C, Gasperini C. Prosperini L, et al. J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):271-277. doi: 10.1136/jnnp-2019-322348. Epub 2020 Jan 23. J Neurol Neurosurg Psychiatry. 2020. PMID: 31974130
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
Goodin DS, Reder AT, Traboulsee AL, Li DK, Langdon D, Cutter G, Cook S, O'Donnell T, Kremenchutzky M, Oger J, Koelbach R, Pohl C, Wicklein EM; IFNB Multiple Sclerosis Study Group and the 16- and 21-Year LTF Investigators. Goodin DS, et al. Mult Scler. 2019 May;25(6):837-847. doi: 10.1177/1352458518773511. Epub 2018 May 15. Mult Scler. 2019. PMID: 29761737
Assessing response to interferon-β in a multicenter dataset of patients with MS.
Sormani MP, Gasperini C, Romeo M, Rio J, Calabrese M, Cocco E, Enzingher C, Fazekas F, Filippi M, Gallo A, Kappos L, Marrosu MG, Martinelli V, Prosperini L, Rocca MA, Rovira A, Sprenger T, Stromillo ML, Tedeschi G, Tintorè M, Tortorella C, Trojano M, Montalban X, Pozzilli C, Comi G, De Stefano N; MAGNIMS study group. Sormani MP, et al. Neurology. 2016 Jul 12;87(2):134-40. doi: 10.1212/WNL.0000000000002830. Epub 2016 Jun 15. Neurology. 2016. PMID: 27306626
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B; REGARD study group. Mikol DD, et al. Lancet Neurol. 2008 Oct;7(10):903-14. doi: 10.1016/S1474-4422(08)70200-X. Epub 2008 Sep 11. Lancet Neurol. 2008. PMID: 18789766 Clinical Trial.
117 results